Company
Since 1909, Grifols has worked to improve the health and well-being of people around the world.
Corporate Structure
Innovation
Grifols is full speed ahead on developing the next innovative breakthroughs across multiple therapeutic areas.
Sustainability
Grifols' longstanding commitment to people and the planet entails helping society on all fronts.
Investors
Stock Information
Financials
Communications with CNMV and SEC
Corporate Governance
Careers
People are at the heart of our business. We are committed to continued investment in training and development.
Media
Latest news about the company and contact information for journalists and communication professionals.
Suppliers
At Grifols, we believe in long-term, mutually trusting relationships with our partners.
Connect with us
Showing 542 search results
Grifols reports revenues of EUR 7,524m, up 7%, and more than doubles Group profit to EUR 402m
Grifols Welcomes Moody’s Ratings’ Upgrade to B1 with Stable Outlook
Grifols receives US FDA approval for new fibrinogen concentrate, FESILTYTM (fibrinogen, human-chmt)
Grifols Welcomes S&P Global Ratings’ Upgrade to ‘BB-’ with Stable Outlook
Grifols obtains approval from the European Medicines Agency for the entire value chain of Grifols Egypt
Egypt achieves self-sufficiency in plasma-derived medicines thanks to Grifols
Grifols appoints Tomás Dagá as Vice President of the board of Grifols Egypt (GEPD) and accelerates plasma self-sufficiency for 2026
Grifols brings together companies and organizations to address the challenges of employment for people with disabilities
Grifols receives expanded indication for THROMBATE III® (antithrombin III [human]) label in U.S., strengthening treatment options for pediatric patients
Grifols’ Biotest receives first regulatory approval for its fibrinogen concentrate
Grifols Secures 95% of Investor Support to Improve Documentation Terms of Its €1.3 Billion 7.5% Secured Notes
Grifols Welcomes Fitch Ratings’ Outlook Revision to Positive and Affirmation of 'B+' Rating